FDA Clears New Blood Test to Aid Alzheimer’s Diagnosis
A new blood test, Lumipulse, has been cleared by the FDA to aid in the diagnosis of Alzheimer's disease for individuals aged 55 and older experiencing cognitive decline. This less invasive method detects amyloid plaque, a key marker of the…
Terre Haute, IN, November 9, 2026 — The U.S. Food and Drug Administration (FDA) has granted clearance for Lumipulse, a new blood test designed to assist in the diagnosis of Alzheimer’s disease.
The test is intended for use in individuals aged 55 years and older who are experiencing cognitive decline. Lumipulse functions by detecting amyloid plaque, which is recognized as a key biological marker associated with Alzheimer’s disease.
This development introduces a less invasive method for evaluating individuals for the condition. Early detection is considered crucial for enabling patients and their healthcare providers to engage in better planning for care and to explore potential treatment interventions.
However, the Lumipulse test is not intended to be used as a standalone diagnostic tool. Its role is to support medical professionals in identifying the disease when used in conjunction with other established medical assessments and diagnostic procedures.
Story summarized from the original created by LeAnne Gendreau on www.wthitv.com, see more information here.
Media gallery
.jpg?branch=production)